OVERACTIVE BLADDER THERAPEUTICS MARKET ANALYSIS

Market News

An increase in the geriatric population and increasing awareness about available treatments for overactive bladder syndrome are the major driver of market growth for overactive bladder therapeutics. For instance, according to the National Association for Continence, in 2018, 1 in 3 adults over the age of 30 suffered from nocturia globally. In addition, according to a report published by the the U.S. Department of Health & Human Services 2018, around 25 million individuals in the U.S. suffered from urinary incontinence

Major key players involved in the manufacturing of overactive bladder therapeutics have been adopting various aggressive business strategies such as collaboration, acquisitions, product launch, product approvals and patents. This helps to provide a positive push towards growth of the market. For instance, in May 2018 Astellas Pharma Inc., received the U.S. Food and Drug Administration (U.S. FDA) approval for use of mirabegron in combination with solifenacin succinate to treat symptoms associated with overactive bladder syndrome. Moreover, in February 2020, Allergan, an AbbVie company launched their U.S. FDA approved Botox for the treatment of overactive bladder syndrome in patients who were either intolerant or did not respond well to commonly used anticholinergic and beta-3 adrenergic drugs. Botox is the first U.S. FDA approved neurotoxin used in the treatment of overactive bladder syndrome in children.

In addition, U.S. FDA is aiming at increasing the number of approvals for generic drugs as well as reducing the cost for the same in order to encourage more companies to launch their drugs into the market. For instance, in December 2020 Urovant Sciences received U.S. FDA approval for GEMTESA (Vibegron) to treat symptoms of urinary urgency, leakage and high urinary frequency in adults suffering from overactive bladder syndrome. 

Also, robust pipeline of drugs which are currently under phase II and III clinical trials that would be expected to be launched soon thus offering a lucrative growth for overactive bladder syndrome therapeutic market. For instance, in 2018 Taris Biomedical LLC entered the phase II clinical trials for its drug candidate TAR-302 which is claimed to be highly effective and exhibit fewer side effects than other available drugs in the market for the treatment of overactive bladder syndrome.